SANGAMO THERAPEUTICS, INC - Common Stock (SGMO)

Q3 2023 13F Holders as of 30 Sep 2023

Type / Class
Equity / Common Stock
Shares outstanding
294,683,714
Total 13F shares
102,314,735
Share change
-3,530,192
Total reported value
$61,341,591
Put/Call ratio
123%
Price per share
$0.60
Number of holders
131
Value change
-$4,250,211
Number of buys
42
Number of sells
73

Institutional Holders of SANGAMO THERAPEUTICS, INC - Common Stock (SGMO) as of Q3 2023

As of 30 Sep 2023, SANGAMO THERAPEUTICS, INC - Common Stock (SGMO) was held by 131 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 102,314,735 shares. The largest 10 holders included WASATCH ADVISORS LP, BlackRock Inc., VANGUARD GROUP INC, Rokos Capital Management LLP, CITADEL ADVISORS LLC, CREDIT SUISSE AG/, GEODE CAPITAL MANAGEMENT, LLC, ACADIAN ASSET MANAGEMENT LLC, STATE STREET CORP, and D. E. Shaw & Co., Inc.. This page lists 131 institutional shareholders reporting positions in this security for the Q3 2023 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.